Autophagy Involvement in Olanzapine-Mediated Cytotoxic Effects in Human Glioma Cells

  • Wang, Yi-Xuan (Department of Pharmacology, School of Pharmaceutical Sciences, Soochow University) ;
  • Xu, Shu-Qing (Department of Pharmacology, School of Pharmaceutical Sciences, Soochow University) ;
  • Chen, Xiang-Hui (Department of Pharmacology, School of Pharmaceutical Sciences, Soochow University) ;
  • Liu, Rui-Si (Department of Pharmacology, School of Pharmaceutical Sciences, Soochow University) ;
  • Liang, Zhong-Qin (Department of Pharmacology, School of Pharmaceutical Sciences, Soochow University)
  • Published : 2014.10.23


The aim of this study was to investigate the effects of olanzapine on growth inhibition as well as autophagy in glioma cells in vitro and in vivo. The proliferation of both LN229 and T98 glioma cells, measured by MTT assay, was suppressed in a concentration-dependent and time-dependent manner. Moreover, apoptosis of both cells was significantly increased with the treatment of olanzapine as evidenced by increased Bcl-2 expression, Hoechst 33258 staining and annexinV-FITC/PI staining. Olanzapine treatment also enhanced activation of autophagy with increased expression of LC3-II, expression of protein p62, a substrate of autophagy, being decreased. The growth inhibition by olanzapine in both glioma cell lines could be blocked by co-treatment with 3-MA, an autophagy inhibitor. Furthermore, olanzapine effectively blocked the growth of subcutaneous xenografts of LN229 glioma cells in vivo. The increased level of protein LC3-II and decreased level of p62 followed by a decreased level of Bcl-2, suggesting that autophagy may contribute to apoptosis. In addition, reduced proliferation of glioma cells was shown by a decrease of Ki-67 staining and increased caspase-3 staining indicative of apoptosis in mouse xenografts. These results indicated that olanzapine inhibited the growth of glioma cells accompanied by induction of autophagy and apoptosis both in vitro and in vivo. Olanzapine-induced autophagy plays a tumor-suppressing role in glioma cells.




Supported by : National Natural Science Foundation of China


  1. Alers S, Loffler AS, Wesselborg S, Stork B (2012). Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol, 32, 2-11.
  2. Bialik S, Kimchi A (2010). Lethal weapons: DAP-kinase, autophagy and cell death: DAP-kinase regulates autophagy. Curr Opin Cell Biol, 22, 199-205.
  3. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.
  4. Cohrs S (2008). Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs, 22, 939-62.
  5. Errafiy R, Aguado C, Ghislat G, et al (2013). PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity. PLoS One, 8, 83318.
  6. Fioretti B, Catacuzzeno L, Sforna L, et al (2009). Histamine hyperpolarizes human glioblastoma cells by activating the intermediate-conductance $Ca_2$-activated K+ channel. Am J Physiol Cell Physiol, 297, C102-10.
  7. Katsetos CD, Draberova E, Smejkalova B, et al (2007). Class III beta-tubulin and gamma-tubulin are co-expressed and form complexes in human glioblastoma cells. Neurochem Res, 32, 1387-98.
  8. Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP (2009). Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology, 207, 119-25.
  9. Levine B, Kroemer G (2008). Autophagy in the pathogenesis of disease. Cell, 132, 27-42.
  10. Li L, Kracht J, Peng S, Bernhardt G, Buschauer A (2003). Synthesis and pharmacological activity of fluorescent histamine H1 receptor antagonists related to mepyramine. Bioorg Med Chem Lett, 13, 1245-8.
  11. Liang C, Feng P, Ku B, et al (2006). Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol, 8, 688-99.
  12. Liang J, Shao SH, Xu ZX, et al (2007). The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol, 9, 218-24.
  13. Mizushima N, Levine B, Cuervo AM, Klionsky DJ (2008). Autophagy fights disease through cellular self-digestion. Nature, 451, 1069-75.
  14. Lum JJ, Bauer DE, Kong M, et al (2005). Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell, 120, 237-48.
  15. Luo Z, Zang M, Guo W (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol, 6, 457-70.
  16. Mathew R, Karantza-Wadsworth V, White E (2007). Role of autophagy in cancer. Nat Rev Cancer, 7, 961-7.
  17. Navari RM (2014). Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol, 722, 180-6.
  18. Nicolau-Galmes F, Asumendi A, Alonso-Tejerina E, et al (2011). Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms. Apoptosis, 16, 1253-67.
  19. Pandey S, Chandravati (2012). Autophagy in cervical cancer: an emerging therapeutic target. Asian Pac J Cancer Prev, 13, 4867-71.
  20. Rabinowitz JD, White E (2010). Autophagy and metabolism. Science, 330, 1344-8.
  21. Ryu CH, Yoon WS, Park KY, et al (2012). Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol, 2012, 987495.
  22. Schmidt RH, Jokinen JD, Massey VL, et al (2013). Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs. J Pharmacol Exp Ther, 347, 126-35.
  23. Yang Z, Klionsky DJ (2010). Eaten alive: a history of macroautophagy. Nat Cell Biol, 12, 814-22.
  24. Skrede S, Martins L, Berge RK, et al (2014). Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. Int J Neuropsychopharmacol, 17, 91-104.
  25. Stupp R, Hegi ME, Mason WP, et al (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol, 10, 459-66.
  26. Wang JB, Dong DF, Wang MD, Gao K (2014). IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in glioma cells in vitro and in vivo. Asian Pac J Cancer Prev, 15, 427-32.
  27. Zhang JP, Gallego JA, Robinson DG, et al (2013). Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol, 16, 1205-18.
  28. Zhang WB, Wang Z, Shu F, et al (2010). Activation of AMPactivated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem, 285, 40461-71.
  29. Zhou X, Ikenoue T, Chen X, et al (2009). Rheb controls misfolded protein metabolism by inhibiting aggresome formation and autophagy. Proc Natl Acad Sci USA, 106, 8923-8.
  30. Zhuang W, Li B, Long L, et al (2011). Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer, 129, 2720-31.

Cited by

  1. Norcantharidin Inhibits SK-N-SH Neuroblastoma Cell Growth by Induction of Autophagy and Apoptosis vol.16, pp.1, 2017,
  2. Rottlerin-induced autophagy leads to apoptosis in bladder cancer cells vol.12, pp.6, 2016,